Clinical trial
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or…
NCT00002912 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00002912 |
|---|---|
| Title | Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia |
| Official title | A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | etoposide, mitoxantrone hydrochloride, valspodar |
| Enrollment | 3 |
| Start date | Jan 1, 1997 |
| Primary completion | Mar 1, 2006 |
| First posted | Apr 29, 2004 |
| Last update posted | Feb 1, 2013 |
| Countries | Australia, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: